Drug name - Striverdi Respimat
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7491719 | BOEHRINGER INGELHEIM | Enantiomerically pure beta agonists, process for the manufacture thereof, and use thereof as medicaments |
Nov, 2023
(1 year, 1 month from now) | |
| US7056916 | BOEHRINGER INGELHEIM | Medicaments for the treatment of chronic obstructive pulmonary disease |
Dec, 2023
(1 year, 2 months from now) | |
| US7220742 | BOEHRINGER INGELHEIM | Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments |
May, 2025
(2 years from now) | |
| US7727984 | BOEHRINGER INGELHEIM | Medicaments for the treatment of chronic obstructive pulmonary disease |
Jan, 2027
(4 years from now) | |
| CN1713914A | BOEHRINGER INGELHEIM | New Medicine For Treating Chronic Obstructive Pulmonary Disease |
Aug, 2010
(12 years ago) | |
| CN101133039A | BOEHRINGER INGELHEIM | Novel Enantiomer Pure Beta-Agonists And Preparation Method And Use Thereof In Medicine Form |
Mar, 2013
(9 years ago) | |
| CN102827097B | BOEHRINGER INGELHEIM | Enantiomerically Pure Beta-Agonist, Its Preparation Method And Its Use In The Pharmaceutical Form |
May, 2025
(2 years from now) | |
| CN102827097A | BOEHRINGER INGELHEIM | Novel Enantiomerically Pure Beta-Agonist, Its Preparation Method And Its Use In The Pharmaceutical Form |
May, 2025
(2 years from now) | |
| IN200501999P1 | BOEHRINGER INGELHEIM | Novel Medicaments For The Treatment Of Chronic Obstructive Pulmonary Disease |
Nov, 2023
(1 year, 1 month from now) | |
| IN225518B | BOEHRINGER INGELHEIM | Novel Substitued [1,1-Dimethyl-Ethyl-Amino)-I-Hydroxy-Ethyl]-6-Hydroxy-4H-Benzo[1,4]Oxazin-3-Ones) Compounds |
Nov, 2023
(1 year, 1 month from now) | |
| EP1562603A2 | BOEHRINGER INGELHEIM | Novel Medicaments For The Treatment Of Chronic Obstructive Pulmonary Diseases |
Jul, 2020
(2 years ago) | |
| EP1562603B3 | BOEHRINGER INGELHEIM | Novel Medicaments For The Treatment Of Chronic Obstructive Pulmonary Diseases |
Jul, 2020
(2 years ago) | |
| EP1562603B1 | BOEHRINGER INGELHEIM | Novel Medicaments For The Treatment Of Chronic Obstructive Pulmonary Diseases |
Jul, 2020
(2 years ago) | |
| EP1789405B1 | BOEHRINGER INGELHEIM | Novel Enantiomerically Pure Beta-Agonists, Method For The Production And The Use Thereof In The Form Of A Drug |
May, 2025
(2 years from now) | |
| EP1789405A1 | BOEHRINGER INGELHEIM | Novel Enantiomerically Pure Beta-Agonists, Method For The Production And The Use Thereof In The Form Of A Drug |
May, 2025
(2 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7786111 | BOEHRINGER INGELHEIM | Medicaments for the treatment of chronic obstructive pulmonary disease |
Nov, 2023
(1 year, 1 month from now) | |
| US8044046 | BOEHRINGER INGELHEIM | Medicaments for the treatment of chronic obstructive pulmonary disease |
Nov, 2023
(1 year, 1 month from now) | |
| US7284474 | BOEHRINGER INGELHEIM | Piston-pumping system having o-ring seal properties |
Aug, 2024
(1 year, 10 months from now) | |
| US8034809 | BOEHRINGER INGELHEIM | Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments |
May, 2025
(2 years from now) | |
| US7896264 | BOEHRINGER INGELHEIM | Microstructured high pressure nozzle with built-in filter function |
May, 2025
(2 years from now) | |
| US7396341 | BOEHRINGER INGELHEIM | Blocking device for a locking stressing mechanism having a spring-actuated output drive device |
Oct, 2026
(4 years from now) | |
| US9027967 | BOEHRINGER INGELHEIM | Device for clamping a fluidic component |
Mar, 2027
(4 years from now) | |
| US7837235 | BOEHRINGER INGELHEIM | Device for clamping a fluidic component |
Mar, 2028
(5 years from now) | |
| US8733341 | BOEHRINGER INGELHEIM | Atomizer and method of atomizing fluid with a nozzle rinsing mechanism |
Oct, 2030
(8 years from now) | |
Drugs and Companies using OLODATEROL HYDROCHLORIDE ingredient
Treatment: Treatment of chronic obstructive pulmonary disease (copd), chronic bronchitis or emphysema
Dosage: SPRAY, METERED;INHALATION
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| EQ 0.0025MG BASE/INH | SPRAY, METERED;INHALATION | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.